The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities

Journal of Pharmaceutical Policy and Practice

Short Report

Roland Djang’eing’a Marini¹  Raffaella Ravinetto²  Richard Cizungu Neci³  Patient Ciza Hamuli⁴  Pernette Bourdillon Esteve⁵  Cécile Macé⁶  Omar Serigne Sarr⁷  Jean-Baptiste Nikiema⁸ 

[1]CIRM, VibraSante Hub, Department of Pharmacy, Laboratory of Pharmaceutical Analytical Chemistry, University of Liege, Liege, Belgium

[2]Department of Public Health, Institute of Tropical Medicine, 2000, Antwerp, Belgium

[3]School of Public Health, University of the Western Cape, Cape Town, South Africa

[4]Ecumenical Pharmaceutical Network (EPN), Nairobi, Kenya

[5]Faculty of Pharmaceutical Sciences, LACOMEDA, University of Kinshasa, Kinshasa, Democratic Republic of Congo

[6]Incidents and Substandard/Falsified Medical Products Team, World Health Organization (WHO), Geneva, Switzerland

[7]Independent Consultant, Nantes, France

[8]University of Dakar Cheikh Anta Diop, Dakar, Senegal

[9]Senegalese Drug Regulatory Agency, Dakar, Senegal

[10]World Health Organization Regional Office for Africa, Brazzaville, Congo

关键词: Medicines;    Drugs;    Medical products;    Substandard;    Falsified;    Regulation;    Pharmacovigilance;    Surveillance;    Africa;   

DOI  :  10.1186/s40545-023-00628-y

 received in 2023-06-20, accepted in 2023-09-30,  发布年份 2023

来源: Springer

【 摘 要 】

Assuring the quality of medical products manufactured, imported or distributed in francophone sub-Saharan Africa remains a challenge, despite positive signals like the growing engagement in the benchmarking of regulatory authorities and -particularly- in the establishment of the African Medicines Agency. In this short report, we describe the existing activities to prevent, detect and respond to substandard and falsified products (SF) in this region, either through African multilateral organizations and initiatives led by the World Health Organization, or through the contribution of other stakeholders, such as local universities and procurement agencies. We underline that these emerging local stakeholders may play a pivotal role to guide and inform the national regulatory authorities about the prevalence and patterns of SF medical products, complementing the market surveillance and control, and building awareness of the importance of pharmaceutical quality assurance for public health.

【 授权许可】

CC BY   
© Dr. Zaheer-Ud-Din Babar and Auckland UniServices Ltd. 2023